We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Medical Solutions Group Plc | LSE:AMS | London | Ordinary Share | GB0004536594 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.40 | 1.24% | 195.40 | 194.80 | 195.60 | 195.60 | 192.00 | 192.40 | 342,131 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 126.21M | 15.89M | 0.0732 | 26.67 | 424M |
TIDMAMS
RNS Number : 1981H
Advanced Medical Solutions Grp PLC
05 June 2017
5 June 2017
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that it was notified on 31 May 2017 that Chris Meredith, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Chris Meredith, also sold Ordinary Shares of 5p each on 31 May 2017 at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise.
As a result of these transactions Chris Meredith's beneficial interest in the Company has increased from 1,192,508 shares to 1,384,841 shares.
Long Term Incentive Plan (LTIP)
Director No. of LTIPs Ordinary Ordinary LTIPs LTIPs prior exercised Shares shares after to exercise sold retained exercise ------------------ ------------- ----------- --------- ---------- ---------- Chris Meredith, Chief Executive Officer 1,078,007 445,814 271,049 174,765 632,193 ------------------ ------------- ----------- --------- ---------- ----------
Deferred Share Bonus Plan (DSB)
Director No. of DSBs DSBs exercised Ordinary DSBs after prior to Shares exercise exercise sold ------------------ ------------ --------------- --------- ----------- Chris Meredith, Chief Executive Officer 32,686 17,568 Nil 15,118 ------------------ ------------ --------------- --------- -----------
Overall holding
Director Holding Number Number Sale Resultant % of prior of shares of shares price holding issued to exercise exercised sold (p) share capital ----------------- ------------- ----------- ----------- --------- ---------- --------- Chris Meredith, Chief Executive Officer 1,192,508 463,382 271,409 277.554p 1.384,841 0.65% ----------------- ------------- ----------- ----------- --------- ---------- ---------
The Company further announces that it was notified on 31 May 2017 that Mary Tavener, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Mary Tavener, also sold Ordinary Shares of 5p each on 31 May 2017 as detailed below at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise.
As a result of these transactions Mary Tavener's beneficial interest in the Company has increased from 1,829,813 shares to 1,890,647 shares.
Long Term Incentive Plan (LTIP)
Director No. of LTIPs Ordinary Ordinary LTIPs LTIPs prior exercised Shares shares after to exercise sold retained exercise ------------------ ------------- ----------- --------- ---------- ---------- Mary Tavener, Chief Financial Officer 675,961 199,319 148,423 50,896 476,642 ------------------ ------------- ----------- --------- ---------- ----------
Deferred Share Bonus Plan (DSB)
Director No. of DSBs DSBs exercised Ordinary DSBs after prior to Shares exercise exercise sold ------------------ ------------ --------------- --------- ----------- Mary Tavener, Chief Financial Officer 19,203 9,938 Nil 9,265 ------------------ ------------ --------------- --------- -----------
Overall holding
Director Holding Number Number Sale Resultant % of prior of shares of shares price holding issued to exercise exercised sold (p) share capital --------------- ------------- ----------- ----------- --------- ---------- --------- Mary Tavener, Chief Financial Officer 1,829,813 209,257 148,423 277.554p 1,890,647 0.89% --------------- ------------- ----------- ----------- --------- ---------- ---------
The Company further announces that it was notified on 31 May 2017 that Eddie Johnson, who is a Senior Manager and PDMR, had exercised 6,243 Ordinary Shares of 5p from the Deferred Share Bonus Plan and sold 9,704 shares as detailed below at a share price of 277.554p per Ordinary Share.
Following these transactions the beneficial ownership of Eddie Johnson is as follows:
Deferred Share Bonus Plan (DSB)
PDMR No. of DSBs DSBs exercised Ordinary DSBs after prior to Shares exercise exercise sold --------------- ------------ --------------- --------- ----------- Eddie Johnson 59,237 6,243 6,243 52,994 --------------- ------------ --------------- --------- -----------
Overall holding
PDMR Holding Number of Sale Resultant % of issued prior to shares sold price holding share exercise (p) capital --------------- ---------- ------------- --------- ---------- ------------ Eddie Johnson 52,195 3,461 277.554p 48,734 0.023% --------------- ---------- ------------- --------- ---------- ------------
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities/person closely associated --- ------------------------------------------------------------ a) Name: Chris Meredith --- ------------------------------------------------------------ 2. Reason for the notification --- ------------------------------------------------------------ a) Position/status: Director/PDMR --- ------------------------------------------------------------ b) Initial notification/Amendment: Initial Notification --- ------------------------------------------------------------ 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ------------------------------------------------------------ a) Name: Advanced Medical Solutions Group plc --- ------------------------------------------------------------ b) LEI: 213800HJP6OWOSZI1L74 --- ------------------------------------------------------------ 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------ a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 --- ------------------------------------------------------------ b) Nature of the transactions: * Exercise of 445,814 shares from the Long Term Incentive Plan * Exercise of 17,568 shares from the Deferred Share Bonus Plan * Sale of 271,049 Ordinary Shares of 5p --- ------------------------------------------------------------ c) Price(s) and volume(s): Sale of shares: Price(s) Volume(s) ------------ ---------- GBP2.77554 271,049 ------------ ---------- --- ------------------------------------------------------------ d) Aggregated information: (Relates to those shares sold only) Aggregated volume: 271,049 Aggregated price: GBP2.77554 --- ------------------------------------------------------------ e) Date of the transaction: 31/05/2017 --- ------------------------------------------------------------ f) Place of the transaction: London Stock Exchange, AIM Market (XLON) --- ------------------------------------------------------------ 1. Details of the person discharging managerial responsibilities/person closely associated --- ----------------------------------------------------------- a) Name: Mary Tavener --- ----------------------------------------------------------- 2. Reason for the notification --- ----------------------------------------------------------- a) Position/status: Director/PDMR --- ----------------------------------------------------------- b) Initial notification/Amendment: Initial Notification --- ----------------------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- -----------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc --- ----------------------------------------------------------- b) LEI: 213800HJP6OWOSZI1L74 --- ----------------------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ----------------------------------------------------------- a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 --- ----------------------------------------------------------- b) Nature of the transactions: * Exercise of 199,319 shares from the Long Term Incentive Plan * Exercise of 9,938 shares from the Deferred Share Bonus Plan * Sale of 148,423 Ordinary Shares of 5p --- ----------------------------------------------------------- c) Price(s) and volume(s): Sale of shares: Price(s) Volume(s) ------------ ---------- GBP2.77554 148,423 ------------ ---------- --- ----------------------------------------------------------- d) Aggregated information: (Relates to those shares sold only) Aggregated volume: 148,423 Aggregated price: GBP2.77554 --- ----------------------------------------------------------- e) Date of the transaction: 31/05/2017 --- ----------------------------------------------------------- f) Place of the transaction: London Stock Exchange, AIM Market (XLON) --- ----------------------------------------------------------- 1. Details of the person discharging managerial responsibilities/person closely associated --- ----------------------------------------------------------- a) Name: Eddie Johnson --- ----------------------------------------------------------- 2. Reason for the notification --- ----------------------------------------------------------- a) Position/status: Senior Manager/PDMR --- ----------------------------------------------------------- b) Initial notification/Amendment: Initial Notification --- ----------------------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ----------------------------------------------------------- a) Name: Advanced Medical Solutions Group plc --- ----------------------------------------------------------- b) LEI: 213800HJP6OWOSZI1L74 --- ----------------------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ----------------------------------------------------------- a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 --- ----------------------------------------------------------- b) Nature of the transaction: * Exercise of 6.243 shares from the Deferred Share Bonus Plan * Sale of 9,704 Ordinary Shares of 5p --- ----------------------------------------------------------- c) Price(s) and volume(s): Sale of shares: Price(s) Volume(s) ------------ ---------- GBP2.77554 9,704 ------------ ---------- --- ----------------------------------------------------------- d) Aggregated information: (Relates to those shares sold only) Aggregated volume: 9,704 Aggregated price: GBP2.77554 --- ----------------------------------------------------------- e) Date of the transaction: 31/05/2017 --- ----------------------------------------------------------- f) Place of the transaction: London Stock Exchange, AIM Market (XLON) --- -----------------------------------------------------------
-End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group Tel: +44 (0) plc 1606 545508 Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer Consilium Strategic Communications Tel: +44 (0) 20 3709 5700 Mary-Jane Elliott / Jonathan AMS@consilium-comms.com Birt / Matthew Neal / Hendrik Thys Investec Bank plc(NOMAD & Broker) Tel: +44 (0) 20 7597 5970 Daniel Adams / Patrick Robb
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal(R) , and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand(R) and RESORBA(R) .
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 600 employees. For more information, please see www.admedsol.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBLGDLXUGBGRU
(END) Dow Jones Newswires
June 05, 2017 13:00 ET (17:00 GMT)
1 Year Advanced Medical Solutions Chart |
1 Month Advanced Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions